Plasma Exchange as an Effective Salvage Treatment for Atypical IEC-HS Complicating CAR-T Therapy in Multiple Myeloma: A Case Report and Literature Review

Abstract Relapsed/refractory multiple myeloma (RRMM) poses substantial therapeutic challenges, and chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment modality. However, CAR-T therapy is often complicated by life-threatening adverse events, most notably cytokine release syndrome (CRS) and secondary hemophagocytic lymphohistiocytosis(sHLH). However distinguishing atypical Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome(IEC-HS) from conventional CRS or sHLH remains clinically difficult but is critical for patient survival. Their overlapping clinical manifestations frequently complicate accurate diagnosis and clinical management. Here, we report a patient who developed an extremely elevated interleukin-6 (IL-6) level (1,227,475 pg/mL) during CAR-T therapy and concurrently met all key diagnostic criteria for sHLH, leading to a diagnosis of severe CRS complicated with sHLH, which was atypical IEC-HS. After three courses of tocilizumab treatment proved ineffective, therapeutic plasma exchange (TPE) was performed and successfully alleviated the severe adverse events associated with CAR-T therapy. These findings indicate that TPE represents a viable therapeutic option for the atypical IEC-HS following CAR-T infusion. We comprehensively explored the diagnosis of CRS combined with sHLH in RRMM patients after CAR-T therapy through the treatment process of individual cases, with a focus on analyzing the therapeutic effect of plasma exchange. This review aims to provide evidence-based guidance and decision support for clinicians to manage these complex and potentially fatal complications, ultimately improving the prognosis of patients with atypical IEC-HS in RRMM after CAR-T therapy.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11462925/v1
Primary Topic
CAR-T cell therapy research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Plasma Exchange as an Effective Salvage Treatment for Atypical IEC-HS Complicating CAR-T Therapy in Multiple Myeloma: A Case Report and Literature Review

杨二晴, 赵变锋, Songyun Wang, Jie Li et al.
3 links
Research Square
CAR-T cell therapy research
preprint

Plasma Exchange as an Effective Salvage Treatment for Atypical IEC-HS Complicating CAR-T Therapy in Multiple Myeloma: A Case Report and Literature Review

杨二晴, 赵变锋, Songyun Wang, Jie Li, Tianjiao Wu, Zesong Wang, Haoyang Ma, Huirui Wang, Shuangshuang Chen, Yuanyuan Jiao
preprint en

Abstract

Abstract Relapsed/refractory multiple myeloma (RRMM) poses substantial therapeutic challenges, and chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment modality. However, CAR-T therapy is often complicated by life-threatening adverse events, most notably cytokine release syndrome (CRS) and secondary hemophagocytic lymphohistiocytosis(sHLH). However distinguishing atypical Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome(IEC-HS) from conventional CRS or sHLH remains clinically difficult but is critical for patient survival. Their overlapping clinical manifestations frequently complicate accurate diagnosis and clinical management. Here, we report a patient who developed an extremely elevated interleukin-6 (IL-6) level (1,227,475 pg/mL) during CAR-T therapy and concurrently met all key diagnostic criteria for sHLH, leading to a diagnosis of severe CRS complicated with sHLH, which was atypical IEC-HS. After three courses of tocilizumab treatment proved ineffective, therapeutic plasma exchange (TPE) was performed and successfully alleviated the severe adverse events associated with CAR-T therapy. These findings indicate that TPE represents a viable therapeutic option for the atypical IEC-HS following CAR-T infusion. We comprehensively explored the diagnosis of CRS combined with sHLH in RRMM patients after CAR-T therapy through the treatment process of individual cases, with a focus on analyzing the therapeutic effect of plasma exchange. This review aims to provide evidence-based guidance and decision support for clinicians to manage these complex and potentially fatal complications, ultimately improving the prognosis of patients with atypical IEC-HS in RRMM after CAR-T therapy.

Research Square
Henan University of Science and Technology (CN)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon